Primary Prevention of Cardiovascular Diseases Clinical Trial
Official title:
Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study
This study aims to describe the demographic characteristics and current status of the aspirin use for primary and secondary prevention of cardiovascular diseases in a large, multicenter nationwide study
Although the benefit of aspirin use for secondary prevention is well established, its role in
the primary prevention of cardiovascular diseases remains controversial. Differences in
primary prevention guidelines may lead to underuse of aspirin in high-risk patients and
overuse in low-risk patients. This study aims to describe the demographic characteristics and
current status of the aspirin use for primary and secondary prevention of cardiovascular
diseases in a large, multicenter nationwide study. The ASSOS trial (Appropriateness of
Aspirin Use in Medical Outpatients: A Multicenter, Observational Study) will be an
observational, multicenter, and non-interventional study conducted in Turkey. Approximately
5000 patients will be enrolled in this non-interventional study. All the data will be
collected at one point in time and current clinical practice will be evaluated.
The investigators will enroll all consecutive patients admitted to the outpatient cardiology
clinics from January 30, 2018, through May 30, 2018, who were at least 18 years of age,
provided written informed consent, and currently treated with aspirin (80-325 mg)within the
last 30 days. Hospital-based cardiologists in public units will be invited to participate in
the study. Patients will be stratified into 2 categories based on the presence or absence of
atherosclerotic cardiovascular disease; secondary prevention group and primary prevention
group, respectively. Appropriateness of aspirin use in primary prevention group will be
evaluated according to the US Preventive Services Task Force (USPSTF) and European Society of
Cardiology (ESC) guidelines. Physicians will complete a standardized survey form to collect
information on patient clinical characteristics, cardiovascular risk factors, medical
history, clinical examination, laboratory test results, and medications. Patients' risk
factors for colorectal cancer and gastrointestinal bleeding will also be questioned.
ASSOS registry will be the largest and most comprehensive study in Turkey evaluating aspirin
use. The results of this study will provide valuable information regarding the potential
misuse of aspirin in a real-world setting.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06408493 -
Peer-led Digital Health Lifestyle Intervention for a Low Income Community at Risk for Cardiovascular Diseases (MYCardio-PEER)
|
N/A |